A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer

被引：0
|
作者：
Steven J. Cohen
Mark M. Zalupski
Manuel R. Modiano
Paul Conkling
Yehuda Z. Patt
Peg Davis
Robert T. Dorr
Michelle L. Boytim
Evan M. Hersh
机构：
[1] Fox Chase Cancer Center,Department of Medical Oncology
[2] University of Michigan,undefined
[3] Arizona Clinical Research Center,undefined
[4] Virginia Oncology Associates,undefined
[5] US Oncology Phase I Group,undefined
[6] University of New Mexico,undefined
[7] University of Arizona,undefined
[8] AmpliMed Corporation,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2010年 / 66卷
关键词：
Gemcitabine; Imexon; Pancreatic cancer; Phase I clinical trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：287 / 294
页数：7
相关论文
共 50 条
  • [31] First-line therapy for advanced pancreatic cancer with gemcitabine and docetaxel versus gemcitabine and erlotinib: A multivariate matched pair analysis.
    Stuebs, P.
    Habermann, P.
    Zierau, K.
    Schuette, K.
    Fahlke, J.
    Ridwelski, K.
    Kettner, E.
    Lippert, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] Sequential gemcitabine and platinum versus first-line combination of gemcitabine and platinum for advanced pancreatic cancer treatment: a retrospective study
    Jhe-Cyuan Guo
    Shih-Hung Yang
    International Journal of Clinical Oncology, 2014, 19 : 634 - 642
  • [33] A phase I study of gemcitabine plus palliative radiation therapy for advanced lung cancer
    Choi, Brian
    Robins, H. Ian
    Schiller, Joan
    Mehta, Minesh
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 63 (01) : 175 - 179
  • [34] A phase I study of gemcitabine plus palliative radiation therapy for advanced lung cancer
    Brian Choi
    H. Ian Robins
    Joan Schiller
    Minesh Mehta
    Cancer Chemotherapy and Pharmacology, 2008, 63 : 175 - 179
  • [35] Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer
    F Cappuzzo
    S Novello
    F De Marinis
    V Franciosi
    M Maur
    A Ceribelli
    V Lorusso
    F Barbieri
    L Castaldini
    E Crucitta
    L Marini
    S Bartolini
    G V Scagliotti
    L Crinò
    British Journal of Cancer, 2005, 93 : 29 - 34
  • [36] Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer
    Cappuzzo, F
    Novello, S
    De Marinis, F
    Franciosi, V
    Maur, M
    Ceribelli, A
    Lorusso, V
    Barbieri, F
    Castaldini, L
    Crucitta, E
    Marini, L
    Bartolini, S
    Scagliotti, GV
    Crinò, L
    BRITISH JOURNAL OF CANCER, 2005, 93 (01) : 29 - 34
  • [37] Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer
    Possinger, K
    Kaufmann, M
    Coleman, R
    Stuart, NSA
    Helsing, M
    Ohnmacht, U
    Arning, M
    ANTI-CANCER DRUGS, 1999, 10 (02) : 155 - 162
  • [38] Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients with EGFR Mutant Advanced NonSmall Cell Lung Cancer
    Zhao, H.
    Zhang, Z.
    Li, S.
    Fang, W.
    Ma, Y.
    Zhang, Y.
    Yang, Y.
    Luo, F.
    Huang, Y.
    Zhang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S506 - S506
  • [39] Preliminary results of a phase I study of sunitinib plus paclitaxel for first-line treatment of advanced breast cancer
    Kozloff, M.
    Chuang, E.
    Roy, J.
    Starr, A.
    Gowland, P. A.
    Tarpey, M. J.
    Collier, M.
    Verkh, L.
    Kern, K.
    Miller, K.
    EJC SUPPLEMENTS, 2007, 5 (04): : 216 - 216
  • [40] Preliminary results of a phase I study of sunitinib plus paclitaxel for first-line treatment of advanced breast cancer
    Kozloff, Mark
    Chuang, Ellen
    Roy, Jessica
    Starr, Alexander
    Gowland, Patricia A.
    Tarpey, Matthew J.
    Collier, Mary
    Verkh, Lev
    Kern, Kenneth
    Miller, Kathy
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3591S - 3591S
12345